Algorithmiq develops end-to-end quantum-classical computing frameworks to simulate complex therapeutics and accelerate drug discovery. The company demonstrated a workflow running on IBM hardware using up to 100 qubits to simulate the activation pathway of a photosensitizer drug currently in Phase II trials. Algorithmiq presented a framework that meets requirements for current-hardware viability, biological relevance, and comparability with modern classical methods. It has partnerships and contributions with Microsoft and IBM, and participated in projects such as the Quantum Advantage Tracker. The company has operations in Italy, Finland, the U.K., Ireland, and the U.S. Dr. Sabrina Maniscalco is CEO and a co-founder.

Total raised

$46M

Funding rounds

5

Latest round

Equity

Latest activity

May 2026